Due to planned maintenance work on our platforms, there might be short service disruptions on Saturday, December 3rd, between 15:00 and 16:00 (CET).

Topic Editors

Prof. Dr. Melanie Kelly
Department of Pharmacology, Dalhousie University, Halifax, NS, Canada
Prof. Dr. Christian Lehmann
Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada

Cannabis, Cannabinoids and Its Derivatives

Abstract submission deadline
31 March 2024
Manuscript submission deadline
30 September 2024
Viewed by
140

Topic Information

Dear Colleagues,

Following the legalization of Cannabis sativa for medicinal use in many countries, modulation of the endocannabinoid system has been the subject of intense research interest. Despite being used since ancient times in traditional Asian medicine, its use in modern pharmacology has only become more commonplace in the last few years. Research into cannabis, cannabinoids, and their derivatives first began in 1964, when Gaoni and Mechoulam identified delta9-tetrahydocannabinol, the main psychoactive ingredient in cannabis. In the 1990s, the cannabinoid type 1 (CB1) receptor was cloned in both rats and humans, followed shortly after by a second cannabinoid receptor (CB2). Endogenous cannabinoid receptor agonists (i.e., anandamide and 2-arachidonoyl glycerol) along with receptors and enzymes for the biosynthesis and degradation of endocannabinoids were then identified, and the endogenous cannabinoid signaling system was termed the “endocannabinoid system”. Since the discovery of endocannabinoids, many synthetic agonists and antagonists, as well as naturally occurring “phytocannabinoids” that target the endocannabinoid system, have been investigated and found to exhibit therapeutic potential in preclinical and clinical studies. This Topic will review and present novel scientific and clinical results regarding the potential therapeutic use of cannabis, cannabinoids, and their derivatives.

Prof. Dr. Melanie Kelly
Prof. Dr. Christian Lehmann
Topic Editors

Keywords

  • endocannabinoid system
  • cannabinoid receptors
  • endocannabinoids
  • phytocannabinoids
  • synthetic cannabinoids
  • terpenes

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biomedicines
biomedicines
4.757 3.0 2013 16.8 Days 2200 CHF Submit
Journal of Clinical Medicine
jcm
4.964 4.4 2012 20.6 Days 2400 CHF Submit
Molecules
molecules
4.927 5.9 1996 14.2 Days 2300 CHF Submit
Pharmaceutics
pharmaceutics
6.525 6.0 2009 15.8 Days 2400 CHF Submit
Scientia Pharmaceutica
scipharm
- 5.3 1930 27.9 Days 1000 CHF Submit
International Journal of Molecular Sciences
ijms
6.208 6.9 2000 15.9 Days 2300 CHF Submit

Preprints is a platform dedicated to making early versions of research outputs permanently available and citable. MDPI journals allow posting on preprint servers such as Preprints.org prior to publication. For more details about reprints, please visit https://www.preprints.org.

Published Papers

This Topic is now open for submission.
Back to TopTop